Silencing of LIM and SH3 Protein 1 (LASP-1) Inhibits Thyroid Cancer Cell Proliferation and Invasion

Figures

• 

  Figure 1. The expression of LASP-1 in thyroid cancer tissues and cell lines. (A, B) The relative expression of LASP-1 in thyroid cancer tissues and matching normal tissues was determined by RT-PCR and Western blot analysis (n = 28). (C, D) The relative expression of LASP-1 in thyroid cancer cell lines (TPC1 and FTC133) and a normal thyroid epithelial cell line (Nthy-ori 3-1) was determined by RT-PCR and Western blot analysis. *p < 0.05.

• 

  Figure 2. The effect of LASP-1 silencing on thyroid cancer cell proliferation in vitro. (A, B) The relative expression of LASP-1 was detected by Western blot analysis after transfection of TPC1 and FTC133 cells with si-LASP-1 or si-NC. (C, D) The proliferation rate of TPC1 and FTC133 cells was remarkably reduced after LASP-1 silencing. *p < 0.05.

• 

  Figure 3. The effect of LASP-1 silencing on thyroid cancer cell migration and invasion in vitro. (A, B) The wound healing assay showed that the migratory capacities of TPC1 and FTC133 cells were reduced after LASP-1 silencing, in comparison with the control cells. (C, D) The Transwell assay revealed that the invasive abilities of TPC1 and FTC133 cells were weakened after LASP-1 silencing, in comparison with the control cells. *p < 0.05.

• 

  Figure 4. The effect of LASP-1 silencing on the activation of PI3K/Akt signaling pathway. (A) The expression levels of p-PI3K, PI3K, p-Akt, and Akt in si-LASP-1-TPC1 and si-NC-TPC1 cells were detected by Western blot analysis. (B) Quantification of p-PI3K/PI3K and p-Akt/Akt. *p < 0.05.

• 

  Figure 5. The effect of LASP-1 silencing on thyroid cancer cell growth in vivo. (A) The volume of tumors was measured every week after subcutaneous injection of si-LASP-1-TPC1 or si-NC-TPC1 cells into nude mice. (B) The histogram presented the mean weight of tumors from the si-LASP-1 and si-NC groups. *p < 0.05.